Billerica, MA and Austin, TX, August 11, 2009 – Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life science industry, today announced that it will begin distributing the new FLEXMAP 3D™ system from Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions. The new system, which was released earlier this year, is a groundbreaking, high-throughput multiplexing instrument that allows scientists to simultaneously perform up to 500 tests on a single sample.
“Luminex has clearly established itself as the leader in multiplex instruments and we are pleased to continue to partner with them to accelerate the evolution of this technology for life science research applications,” said Linda Meeh, Marketing Director for biomarkers and immunoassays at Millipore. “This new instrument, combined with our software and reagent kits, will bring the power of xMAP® Technology to pharmaceutical and other research labs who desire high throughput solutions.”
The FLEXMAP 3D system is designed to meet the needs of medium- and high-volume laboratories, and its ability to conduct many tests at once can significantly enhance the efficiencies of life sciences research and drug discovery.
“Millipore has an extensive global reach that covers academic, reference and pharmaceutical research laboratories, and we are excited to have the company as a distribution partner for the groundbreaking FLEXMAP 3D instrument,” said Darin Leigh, Vice President of Sales and Marketing at Luminex. “Millipore’s commitment to distribute FLEXMAP 3D is indicative of the growth and success of our relationship over the last 10 years, and we appreciate its continued support of our technology. The FLEXMAP 3D will expand Millipore’s xMAP instrument portfolio and its exceptional performance will give the company access to new customers.”
Linco®, which Millipore acquired in 2006, was the original Luminex reagent partner for life science research. Since that acquisition, Millipore has strengthened its commitment to the xMAP platform through its growing line of MILLIPLEX® MAP reagent kits, new analysis software, in-field service, and global sales force.
Based on Luminex’s flexible xMAP Technology, FLEXMAP 3D system fills an essential segment between the low multiplex marketplace and the high multiplex microarray market. The robust system provides scientists at medium and high volume laboratories significantly enhanced throughput; higher multiplexing, with up to 500 analytes per well; improved analytical performance; 96 or 384 well plate format; enhanced dual pipetting, automation and LIS compatibility; streamlined calibration and performance verification routines; and easy maintenance with a simple workflow.
FLEXMAP 3D systems can perform multiplexed genomic, transcriptomic, and proteomic biomarker analysis on a single platform. FLEXMAP 3D system is ideal for applications such as SNP genotyping and gene expression analysis, which are vital in areas such as high throughput pharmaceutical research. By enabling research to proceed more efficiently, the system allows faster screening of novel targets and an overall improvement in laboratory management.
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit www.millipore.com.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company’s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.
